Uteroplacental Adenovirus Vascular Endothelial Growth Factor Gene Therapy Increases Fetal Growth Velocity in Growth-Restricted Sheep Pregnancies
Open Access
- 4 March 2014
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 25 (4) , 375-384
Abstract
Fetal growth restriction (FGR) occurs in ∼8% of pregnancies and is a major cause of perinatal mortality and morbidity. There is no effective treatment. FGR is characterized by reduced uterine blood flow (UBF). In normal sheep pregnancies, local uterine artery (UtA) adenovirus (Ad)-mediated overexpression of vascular endothelial growth factor (VEGF) increases UBF. Herein we evaluated Ad.VEGF therapy in the overnourished adolescent ewe, an experimental paradigm in which reduced UBF from midgestation correlates with reduced lamb birthweight near term. Singleton pregnancies were established using embryo transfer in adolescent ewes subsequently offered a high intake ( n =45) or control intake ( n =12) of a complete diet to generate FGR or normal fetoplacental growth, respectively. High-intake ewes were randomized midgestation to receive bilateral UtA injections of 5×10 11 particles Ad.VEGF-A 165 ( n =18), control vector Ad.LacZ ( n =14), or control saline ( n =13). Fetal growth/well-being were evaluated using serial ultrasound. UBF was monitored using indwelling flowprobes until necropsy at 0.9 gestation. Vasorelaxation, neovascularization within the perivascular adventitia, and placental mRNA expression of angiogenic factors/receptors were examined using organ bath analysis, anti-vWF immunohistochemistry, and qRT-PCR, respectively. Ad.VEGF significantly increased ultrasonographic fetal growth velocity at 3–4 weeks postinjection ( p =0.016–0.047). At 0.9 gestation fewer fetuses were markedly growth-restricted (birthweight >2SD below contemporaneous control-intake mean) after Ad.VEGF therapy. There was also evidence of mitigated fetal brain sparing (lower biparietal diameter-to-abdominal circumference and brain-to-liver weight ratios). No effects were observed on UBF or neovascularization; however, Ad.VEGF-transduced vessels demonstrated strikingly enhanced vasorelaxation. Placental efficiency (fetal-to-placental weight ratio) and FLT1/KDR mRNA expression were increased in the maternal but not fetal placental compartments, suggesting downstream effects on placental function. Ad.VEGF gene therapy improves fetal growth in a sheep model of FGR, although the precise mechanism of action remains unclear.Keywords
This publication has 41 references indexed in Scilit:
- Long-term increase in uterine blood flow is achieved by local overexpression of VEGF-A165 in the uterine arteries of pregnant sheepGene Therapy, 2011
- Ultrasonographic Assessment of Growth and Estimation of Birthweight in Late Gestation Fetal SheepUltrasound in Medicine & Biology, 2011
- Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheepGene Therapy, 2008
- Intrauterine restriction (IUGR)Journal of Perinatal Medicine, 2008
- The expression of ovine placental lactogen, StAR and progesterone-associated steroidogenic enzymes in placentae of overnourished growing adolescent ewesReproduction, 2007
- Racial and Gender Differences in the Viability of Extremely Low Birth Weight Infants: A Population-Based StudyPediatrics, 2006
- A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretationBJOG: An International Journal of Obstetrics & Gynaecology, 2003
- A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretationBJOG: An International Journal of Obstetrics & Gynaecology, 2003
- The EPICure Study: Outcomes to Discharge From Hospital for Infants Born at the Threshold of ViabilityPediatrics, 2000
- Vascular ProtectionArteriosclerosis, Thrombosis, and Vascular Biology, 2000